(5, 65, 66) The TNF-α receptor inhibitor etanercept, approved for various rheumatologic indications, has been shown to abate CRS in case reports of both anti-CD19 and anti-BCMA CAR T cell therapies. This evidence concerns the gene CD19 and congenital rubella syndrome.